Argonaute RNA Ltd — SEC Form D Filing
Argonaute RNA Ltd filed an SEC Form D on September 24, 2026, reporting $1.80M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 24, 2026
- Amount reported
- $1.80M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://argonauterna.com/
What the company does
Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: UNITED KINGDOM
Problem
There are life-threatening areas of clinical unmet need in cardiometabolic diseases that require precise, short-duration gene silencing. Additionally, complex multi-factorial diseases are challenging to treat when silencing only a single gene, and developing stable and effective siRNA drugs for human use has faced significant obstacles.
Solution
Argonaute RNA develops bispecific siRNA therapeutics, including PULSE siRNA™ for acute indications requiring rapid recovery and Argo Dual siRNA for complex multi-factorial diseases. These proprietary modified siRNAs are stabilized to safely and effectively silence specific gene expression by inhibiting protein production, overcoming previous development challenges.
Why now
Advances in RNA interference technology and growing demand for precision medicine solutions allow for the development of more stable and effective siRNA therapeutics for previously untreatable or difficult-to-treat diseases.
Verdict
This cleared because investors saw a credible technical approach to a well-understood biological mechanism, not because the specific clinical targets were de-risked. They implicitly bet on the platform's ability to generate multiple novel drug candidates and attract larger pharmaceutical partners through improved stability and specificity. Upside was limited by the long development cycles inherent in drug discovery and the crowded field of RNA therapeutics, suggesting a platform play rather than a quick clinical win.
Source: SEC EDGAR Form D filing